Vor Bio enters into license pact witht RemeGen for late-stage autoimmune asset
Vor Bio (VOR) and RemeGen announced entry into an exclusive license agreement granting Vor Bio global rights to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125M consisting of an upfront payment of $45M as well as $80M of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4B, in addition to tiered royalties. Telitacicept is a novel, investigational fusion protein that targets key immune pathways involved in autoimmune disease. By selectively inhibiting BlyS and APRIL – cytokines critical to B cell survival – telitacicept reduces autoreactive B cells and autoantibody production. RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Chase Elliott: 'Unbelievable' to win hometown race at EchoPark
Canadian economy pulls back in April Statistics Canada said real gross domestic product edged down 0.1 per cent in April and that its advance estimate for May pointed to a similar decline. The Canadian manufacturing sector posted its largest drop since April 2021 in the face of U.S. tariffs. (June 27, 2025) 1:25 Now Playing Paused Ad Playing
Yahoo
a day ago
- Yahoo
Surprising jobs data shows economy in flux
Surprising jobs data shows economy in flux originally appeared on TheStreet. It's been one "strong job market report" after another. Investors continue dancing to that beat, as we stare down a record high for the S&P 500. 💵💰💰💵 Mr. Market is brushing off any wobble in weekly unemployment claims as mostly seasonal noise. Peel back the curtain, however, and the continuing claims paint a more mixed story about a fragile economic state. The latest jobless claims update drives that point home and could shake the economy. Over the past few months, weekly jobless claims in the U.S. have fallen in a pattern that gives off mixed signals. In early April, initial claims nudged up to 223,000 in the week ending April 5. This represents a modest rise of 4,000, but economists expected the number to remain flat. Businesses were already feeling the heat due to the threat of new tariffs, and March hiring numbers were underwhelming. Just 228,000 jobs were added, with unemployment ticking up to 4.2%.A few weeks later, in late April, things got shakier. Claims rose by 18,000 to 241,000, the highest they'd been in a couple of months. Sure, spring breaks played a part, but beneath the surface, you had corporate America feeling the squeeze from tariffs. May brought its mix of highs and lows as well. Things picked up strongly, with claims dropping by 13,000 to 228,000. By mid-month, filings hovered around 229,000, but by May 24, claims shot up to 240,000, the biggest weekly spike in over a year. It wasn't just about the seasonal hires this time, though. More on Markets: Housing market update spells more trouble Why Thursday's market bell might echo in history Wall Street veteran analyst who predicted stock market rally resets forecast Layoffs were starting to impact areas like transportation and hospitality, once considered safe from recession talk. And June's data felt more like walking a tightrope. The month kicked off with claims climbing to 248,000, and up until last week, the four-week average crept up to 245,500, the highest it's been in nearly two years. That was all before today's update, adding a new twist to the story. For the week ending June 21, initial jobless claims dropped to 236,000, 10,000 lower than the week before and below the 244,000 forecast. That comes with a catch, though, as last week's numbers were quietly revised to 246,000 — a soft win, at best. Meanwhile, continuing claims surged by 37,000 to 1.974 million, the highest since late clearly indicates that more folks are stuck on benefits significantly longer than expected, clipping away at their disposable incomes. Unadjusted state filings dropped 4% to 227,080, again mostly in line with last year once you factor out seasonal noise. Moreover, with the insured unemployment rate at 1.2%, things continue to look bleak for those already out of work. Nevertheless, it seems the markets are shrugging off those darker themes. S&P 500 futures briefly popped to 6,171 earlier today, topping the prior intraday record of 6,166. Hence, Mr. Market's still buying the corporate resilience story, even as the jobless rolls tell a more cautionary jobs data shows economy in flux first appeared on TheStreet on Jun 26, 2025 This story was originally reported by TheStreet on Jun 26, 2025, where it first appeared. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a day ago
- Yahoo
Vor, with new CEO, changes course to target autoimmune disease
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vor Biopharma is licensing rights to an immune disease drug from Chinese biotechnology company RemeGen, it said Wednesday, a little over one month after announcing plans to review strategic alternatives. As part of its shift in focus, Vor also announced it appointed former MorphoSys leader Jean-Paul Kress as CEO. Vor's previous chief executive Robert Ang will stay on as an adviser through October. Vor also raised $175 million in a PIPE, or private investment in public equity, that involved half a dozen investors including RA Capital Management, Forbion and Venrock Healthcare Capital Partners. PureTech Health and the oncologist and author Siddhartha Mukherjee founded Vor nearly a decade ago. Progress developing a treatment for leukemia led the company in 2021 to price a $177 million initial public offering. But a rocky few years forced Vor to change direction. The Cambridge, Massachusetts-based biotech had been advancing cell therapies called trem-cel and VCAR33, but in May revealed plans to wind down clinical operations and lay off 95% of its employees. Now, Vor is reestablishing itself as an autoimmune disease company. The deal with RemeGen gives its rights to develop and commercialize in most parts of the world a drug for generalized myasthenia gravis, systemic lupus erythematosus and rheumatoid arthritis that's already approved in China. Vor is paying RemeGene $45 million upfront along with $80 million in warrants to purchase common stock in exchange for the drug, called telitacicept. Telitacicept is in Phase 3 testing for generalized myasthenia gravis in the U.S., Europe and South America, according to the companies. Data from that trial is expected in 2027. 'I am absolutely thrilled to be leading Vor Bio as we transform the company to become a major player in autoimmune disease treatment,' Kress said in a statement. Telitacicept's targets are cytokines known as BAFF and APRIL, which have also been the focus of other dealmaking. Recently, China-based biotechs like RemeGen are providing more and more of the drug candidates licensed by U.S. and European drugmakers. 'Global biopharma companies can increasingly look to China as a cost-effective source of innovation, particularly for validated targets and rapid generation of proof-of-concept data,' Leerink Partners analyst David Risinger wrote in a Thursday note to clients. Vor's decision to start anew with a Phase 3-ready drug candidate contrasts with the route preferred by some activist investors and analysts, who have pushed struggling biotechs to wind down and return cash to shareholders rather than try to reinvent themselves. Some, like Third Harmonic Bio and iTeos Therapeutics, have taken this course, while others have resisted the pressure 'I couldn't be more thrilled with this exciting new direction for Vor, and new leadership with the background and skills appropriate for this asset,' Ang, Vor's former CEO, wrote in a LinkedIn post. Shares in Vor nearly doubled on the news to trade around $1 apiece by Thursday afternoon. Recommended Reading Biopharma sector still growing despite layoff wave, Stifel report finds
